1.82
price down icon1.09%   -0.02
after-market Handel nachbörslich: 1.84 0.02 +1.10%
loading
Schlusskurs vom Vortag:
$1.84
Offen:
$1.83
24-Stunden-Volumen:
24,937
Relative Volume:
0.82
Marktkapitalisierung:
$1.16M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-44.93M
KGV:
-0.219
EPS:
-8.31
Netto-Cashflow:
$-17.32M
1W Leistung:
-8.08%
1M Leistung:
-44.34%
6M Leistung:
-58.73%
1J Leistung:
-93.56%
1-Tages-Spanne:
Value
$1.76
$1.91
1-Wochen-Bereich:
Value
$1.76
$1.985
52-Wochen-Spanne:
Value
$1.75
$39.38

Ernexa Therapeutics Inc Stock (ERNA) Company Profile

Name
Firmenname
Ernexa Therapeutics Inc
Name
Telefon
(617) 798-6700
Name
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Name
Mitarbeiter
6
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
ERNA's Discussions on Twitter

Vergleichen Sie ERNA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ERNA
Ernexa Therapeutics Inc
1.82 1.16M 598.00K -44.93M -17.32M -8.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten

pulisher
Jun 18, 2025

Ernexa Therapeutics (NASDAQ:ERNA) Shares Up 5.9% – What’s Next? - Defense World

Jun 18, 2025
pulisher
Jun 13, 2025

Sector Update: Health Care - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Ernexa Therapeutics Shares Fall Pre-Bell Following Reverse Stock Split - marketscreener.com

Jun 13, 2025
pulisher
Jun 12, 2025

Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Ernexa Therapeutics announces 1-for-15 reverse stock split By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Eterna Therapeutics Implements 1-for-15 Reverse Stock Split - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Ernexa Therapeutics announces 1-for-15 reverse stock split - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Ernexa Therapeutics registers 57M shares for resale - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Ernexa therapeutics ten percent owner acquires $2.22 million in stock By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Ernexa therapeutics ten percent owner acquires $2.22 million in stock - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Eterna Therapeutics Files for Resale of 57 Million Shares - marketscreener.com

Jun 11, 2025
pulisher
Jun 10, 2025

Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split - citybiz

Jun 10, 2025
pulisher
Jun 10, 2025

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Ernexa Plans 93% Share Reduction in Critical Nasdaq Compliance Move - Stock Titan

Jun 10, 2025
pulisher
Jun 09, 2025

Eterna Therapeutics Completes $6M Private Placement - TipRanks

Jun 09, 2025
pulisher
Jun 02, 2025

Eterna Therapeutics Increases Authorized Shares and Amends Bylaws - TipRanks

Jun 02, 2025
pulisher
May 28, 2025

Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025 - TipRanks

May 28, 2025
pulisher
May 28, 2025

Ernexa Therapeutics to Present Breakthrough Data on iMSC-Based Immunotherapy at ASCO Annual Meeting 2025 - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - GlobeNewswire

May 28, 2025
pulisher
May 14, 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Ernexa's New Texas Hub Accelerates Novel Ovarian Cancer Treatment: MD Anderson Expert Leads Research - Stock Titan

May 14, 2025
pulisher
May 08, 2025

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard

May 08, 2025
pulisher
May 04, 2025

ERNAErnexa Latest Stock News & Market Updates - Stock Titan

May 04, 2025
pulisher
Apr 30, 2025

Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach? - Inside Precision Medicine

Apr 30, 2025
pulisher
Apr 29, 2025

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Revolutionary Stem Cell Therapy Fights Cancer in Two Ways, MD Anderson Study Shows - Stock Titan

Apr 29, 2025
pulisher
Apr 22, 2025

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times

Apr 22, 2025
pulisher
Apr 22, 2025

Revolutionary Tumor-Fighting Cell Therapy: MD Anderson to Present Ernexa's Ovarian Cancer Breakthrough at AACR - Stock Titan

Apr 22, 2025
pulisher
Apr 17, 2025

Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com

Apr 16, 2025
pulisher
Apr 10, 2025

Smart Trial Design In Cell Therapy: Fast-Tracking Without Compromising - Clinical Leader

Apr 10, 2025
pulisher
Apr 05, 2025

Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia

Apr 05, 2025
pulisher
Apr 04, 2025

ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Ernexa Therapeutics Closes New Funding Round - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan

Apr 03, 2025
pulisher
Mar 30, 2025

Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Mar 30, 2025
pulisher
Mar 26, 2025

Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan

Mar 25, 2025
pulisher
Mar 22, 2025

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World

Mar 22, 2025

Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ernexa Therapeutics Inc-Aktie (ERNA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Cherington Charles
10% Owner
Apr 02 '25
Buy
0.10
3,768,397
394,174
20,401,602
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):